Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study
The 177Lu-labeled prostate-specific membrane antigen (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer is under investigation in a phase III trial (VISION: NCT03511664). However, patients with diffuse bone involvement, diagnosed with a “superscan” by bone scintigraphy...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10 June 2020
|
| In: |
European urology
Year: 2020, Jahrgang: 78, Heft: 2, Pages: 148-154 |
| ISSN: | 1873-7560 |
| DOI: | 10.1016/j.eururo.2020.05.004 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.eururo.2020.05.004 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0302283820303444 
|
| Verfasserangaben: | Andrei Gafita, Wolfgang P. Fendler, Wang Hui, Shahneen Sandhu, Manuel Weber, Rouzbeh Esfandiari, Jeremie Calais, Isabel Rauscher, Hendrik Rathke, Robert Tauber, Ebrahim S. Delpassand, Wolfgang A. Weber, Ken Herrmann, Johannes Czernin, Matthias Eiber, Michael S. Hofman |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1728846269 | ||
| 003 | DE-627 | ||
| 005 | 20230426091339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200903s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eururo.2020.05.004 |2 doi | |
| 035 | |a (DE-627)1728846269 | ||
| 035 | |a (DE-599)KXP1728846269 | ||
| 035 | |a (OCoLC)1341358461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gafita, Andrei |e VerfasserIn |0 (DE-588)121703773X |0 (DE-627)1728846714 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement |b a multicenter retrospective study |c Andrei Gafita, Wolfgang P. Fendler, Wang Hui, Shahneen Sandhu, Manuel Weber, Rouzbeh Esfandiari, Jeremie Calais, Isabel Rauscher, Hendrik Rathke, Robert Tauber, Ebrahim S. Delpassand, Wolfgang A. Weber, Ken Herrmann, Johannes Czernin, Matthias Eiber, Michael S. Hofman |
| 264 | 1 | |c 10 June 2020 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel ist "177" in 177Lu-labeled hochgestellt | ||
| 500 | |a Gesehen am 03.09.2020 | ||
| 520 | |a The 177Lu-labeled prostate-specific membrane antigen (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer is under investigation in a phase III trial (VISION: NCT03511664). However, patients with diffuse bone involvement, diagnosed with a “superscan” by bone scintigraphy at baseline, were excluded due to a lack of efficacy and safety data. We therefore aimed to investigate the feasibility of LuPSMA in patients with diffuse bone marrow involvement on baseline PSMA-targeted positron emission tomography. The primary end points were prostate-specific antigen (PSA) response (Prostate Cancer Working Group 3 [PCWG3]), hematologic safety profile (Common Terminology Criteria for Common Adverse Events [CTCAE]), and overall survival. Secondary end points of quality of life (assessed with Brief Pain Inventory-Short Form questionnaires) and radiologic response (Response Evaluation Criteria in Solid Tumors [RECIST]) were assessed. Through retrospective screening of databases, we identified 43 eligible patients across four centers worldwide who received 154 cycles of LuPSMA under clinical trials or compassionate access programs. Median baseline PSA was 1000 (interquartile range 431-2151) ng/ml. PSA decline of at least 50% at 12 wk was achieved in 22 (58%) patients, while median time to pain progression was 8.3 (95% confidence interval [CI] 4.1-12.6) mo. Median overall survival was 11.6 (95% CI 8.8-14.3) mo. Objective response in nodal or visceral disease was reported in seven (39%) of 18 patients with RECIST measurable disease. Grade 3 anemia, thrombocytopenia, and neutropenia occurred in nine (22%), seven (17%), and three (8%) patients, respectively. Grade 4 thrombocytopenia was noticed in three (8%) patients. In conclusion, patients with diffuse bone marrow involvement demonstrated similar LuPSMA efficacy and safety to phase II evidence. Acceptable safety outcomes do not support exclusion of patients with a superscan from future LuPSMA treatment protocols. - Patient summary - In this report, we investigated the feasibility of prostate-specific membrane antigen (PSMA)-directed radionuclide treatment in patients with metastatic castration-resistant prostate cancer and diffuse bone involvement. We found that, despite a high load of bone metastases, PSMA-targeted therapy remains efficacious and safe when compared with the current phase II trial results. | ||
| 650 | 4 | |a Bone marrow involvement | |
| 650 | 4 | |a Lu-labeled prostate-specific membrane antigen | |
| 650 | 4 | |a Metastatic castration-resistant prostate cancer | |
| 650 | 4 | |a Prostate-specific membrane antigen | |
| 650 | 4 | |a Radionuclide treatment | |
| 700 | 1 | |a Fendler, Wolfgang P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hui, Wang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sandhu, Shahneen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weber, Manuel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Esfandiari, Rouzbeh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Calais, Jeremie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rauscher, Isabel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rathke, Hendrik |d 1986- |e VerfasserIn |0 (DE-588)1151445495 |0 (DE-627)1011715392 |0 (DE-576)497748223 |4 aut | |
| 700 | 1 | |a Tauber, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Delpassand, Ebrahim S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weber, Wolfgang A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herrmann, Ken |e VerfasserIn |4 aut | |
| 700 | 1 | |a Czernin, Johannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eiber, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hofman, Michael S. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European urology |d Amsterdam [u.a.] : Elsevier Science, 1976 |g 78(2020), 2, Seite 148-154 |h Online-Ressource |w (DE-627)300191596 |w (DE-600)1482253-2 |w (DE-576)099718103 |x 1873-7560 |7 nnas |a Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement a multicenter retrospective study |
| 773 | 1 | 8 | |g volume:78 |g year:2020 |g number:2 |g pages:148-154 |g extent:7 |a Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement a multicenter retrospective study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.eururo.2020.05.004 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0302283820303444 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200903 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1151445495 |a Rathke, Hendrik |m 1151445495:Rathke, Hendrik |d 910000 |d 911400 |e 910000PR1151445495 |e 911400PR1151445495 |k 0/910000/ |k 1/910000/911400/ |p 9 | ||
| 999 | |a KXP-PPN1728846269 |e 3746337569 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1728846269"],"doi":["10.1016/j.eururo.2020.05.004"]},"origin":[{"dateIssuedDisp":"10 June 2020","dateIssuedKey":"2020"}],"name":{"displayForm":["Andrei Gafita, Wolfgang P. Fendler, Wang Hui, Shahneen Sandhu, Manuel Weber, Rouzbeh Esfandiari, Jeremie Calais, Isabel Rauscher, Hendrik Rathke, Robert Tauber, Ebrahim S. Delpassand, Wolfgang A. Weber, Ken Herrmann, Johannes Czernin, Matthias Eiber, Michael S. Hofman"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Basel","dateIssuedDisp":"1976-","publisher":"Elsevier Science ; Karger","dateIssuedKey":"1976"}],"id":{"eki":["300191596"],"zdb":["1482253-2"],"issn":["1873-7560","1421-993X"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement a multicenter retrospective studyEuropean urology","note":["Ungezählte Beil. bis 40.2001: Supplement"],"recId":"300191596","language":["eng"],"pubHistory":["Nachgewiesen 2.1976 -"],"part":{"year":"2020","issue":"2","pages":"148-154","volume":"78","text":"78(2020), 2, Seite 148-154","extent":"7"},"title":[{"subtitle":"official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology","title":"European urology","title_sort":"European urology"}]}],"physDesc":[{"extent":"7 S."}],"title":[{"title_sort":"Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement","title":"Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement","subtitle":"a multicenter retrospective study"}],"person":[{"given":"Andrei","family":"Gafita","role":"aut","display":"Gafita, Andrei","roleDisplay":"VerfasserIn"},{"given":"Wolfgang P.","family":"Fendler","role":"aut","roleDisplay":"VerfasserIn","display":"Fendler, Wolfgang P."},{"role":"aut","roleDisplay":"VerfasserIn","display":"Hui, Wang","given":"Wang","family":"Hui"},{"family":"Sandhu","given":"Shahneen","display":"Sandhu, Shahneen","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Weber, Manuel","role":"aut","family":"Weber","given":"Manuel"},{"given":"Rouzbeh","family":"Esfandiari","role":"aut","roleDisplay":"VerfasserIn","display":"Esfandiari, Rouzbeh"},{"given":"Jeremie","family":"Calais","role":"aut","roleDisplay":"VerfasserIn","display":"Calais, Jeremie"},{"given":"Isabel","family":"Rauscher","role":"aut","roleDisplay":"VerfasserIn","display":"Rauscher, Isabel"},{"display":"Rathke, Hendrik","roleDisplay":"VerfasserIn","role":"aut","family":"Rathke","given":"Hendrik"},{"role":"aut","display":"Tauber, Robert","roleDisplay":"VerfasserIn","given":"Robert","family":"Tauber"},{"role":"aut","display":"Delpassand, Ebrahim S.","roleDisplay":"VerfasserIn","given":"Ebrahim S.","family":"Delpassand"},{"role":"aut","display":"Weber, Wolfgang A.","roleDisplay":"VerfasserIn","given":"Wolfgang A.","family":"Weber"},{"role":"aut","display":"Herrmann, Ken","roleDisplay":"VerfasserIn","given":"Ken","family":"Herrmann"},{"given":"Johannes","family":"Czernin","role":"aut","roleDisplay":"VerfasserIn","display":"Czernin, Johannes"},{"display":"Eiber, Matthias","roleDisplay":"VerfasserIn","role":"aut","family":"Eiber","given":"Matthias"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Hofman, Michael S.","given":"Michael S.","family":"Hofman"}],"language":["eng"],"recId":"1728846269","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Im Titel ist \"177\" in 177Lu-labeled hochgestellt","Gesehen am 03.09.2020"]} | ||
| SRT | |a GAFITAANDREFFICACYAN1020 | ||